Trisalus Life Sciences, INC Form 4 insider transactions

TriSalus Life Sciences director, Gary B. Gordon, was granted stock options for 41,250 shares on January 29, 2025.

Director William Valle of TriSalus Life Sciences acquired stock options for 41,250 shares of common stock on January 29, 2025.

TriSalus Life Sciences CEO, Mary T. Szela, purchased a total of 10,040 shares of common stock in two separate transactions on January 29th and 30th, 2025.

CEO Mary T. Szela reports acquisition of shares and stock options in TriSalus Life Sciences.

Sean Murphy, a director and officer of TriSalus Life Sciences, reports acquiring shares and options in the company through recent transactions.

Bryan F. Cox, Chief of Research at TriSalus Life Sciences, reports the acquisition of stock options and restricted stock units in the company.

James Emmett Young, CFO of TriSalus Life Sciences, reports acquisition of shares and stock options.

Jodi Devlin, Chief of Commercial Operations at TriSalus Life Sciences, received stock options and restricted stock units on January 27, 2025, according to a recent SEC filing.

Richard Marshak, Chief Commercial Officer of TriSalus Life Sciences, receives restricted stock units and stock options.

Jennifer Stevens, Chief Regulatory Officer of TriSalus Life Sciences, reports the acquisition of restricted stock units and stock options.

Director David J. Matlin received 10,040 restricted stock units in TriSalus Life Sciences in lieu of his 2025 cash board retainer.

Director Liselotte Hyveled received 10,040 restricted stock units (RSUs) from TriSalus Life Sciences in place of her 2025 cash retainer for board service.

Bryan F. Cox, Chief Scientific & Manufacturing Officer at TriSalus Life Sciences, sold 314 shares of common stock to cover tax obligations related to vested restricted stock units.

Director Mats Wahlstrom acquired 25,188 shares of TriSalus Life Sciences common stock at $3.97 per share on December 17, 2024.

Frankenius Equity AB, a 10% owner of TriSalus Life Sciences, Inc., acquired 62,972 shares of common stock at $3.97 per share on December 17, 2024.

An insider at TriSalus Life Sciences sold 30,000 shares of common stock at a weighted average price of $3.69.

Director Mats Wahlstrom purchased 5,000 shares of TriSalus Life Sciences stock at an average price of $4.55.

Director Mats Wahlstrom of TriSalus Life Sciences has increased his holdings through open market purchases of common stock.

Richard Marshak, a Senior Vice President at TriSalus Life Sciences, was granted stock options and restricted stock units as part of his compensation.

Mary T. Szela, CEO and President of TriSalus Life Sciences, recently purchased additional shares of the company's common stock.

TriSalus Life Sciences CEO Mary T. Szela purchased 5,000 shares of TLSI stock at an average price of $4.97 on September 10, 2024.

Director George Kelly Martin reports the sale of common stock held indirectly through Varka LLC.

Mats Wahlstrom, a director of TriSalus Life Sciences, was granted stock options to purchase 15,000 shares of common stock on August 13, 2024.

Liselotte Hyveled, a director of TriSalus Life Sciences, acquired stock options for 15,000 shares on August 13, 2024.

Kerry R. Hicks, a director of TriSalus Life Sciences, acquired stock options for 15,000 shares on August 13, 2024.

Director George Kelly Martin acquired stock options for 15,000 shares of TriSalus Life Sciences, Inc. (TLSI) on August 13, 2024.

Director David J. Matlin reports acquisition of stock options in TriSalus Life Sciences, Inc.

Director Arjun J.J. Desai receives stock options in TriSalus Life Sciences, Inc.

Anil K. Singhal, a director of TriSalus Life Sciences, acquired stock options for 15,000 shares on August 13, 2024.

Andrew C. von Eschenbach, a director of TriSalus Life Sciences, acquired stock options for 15,000 shares on August 13, 2024.